Compare CERT & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | NEO |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 1999 |
| Metric | CERT | NEO |
|---|---|---|
| Price | $9.45 | $12.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $12.78 | $11.38 |
| AVG Volume (30 Days) | 2.0M | ★ 2.0M |
| Earning Date | 02-25-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $415,551,000.00 | ★ $709,162,000.00 |
| Revenue This Year | $10.75 | $10.90 |
| Revenue Next Year | $6.32 | $9.85 |
| P/E Ratio | $140.59 | ★ N/A |
| Revenue Growth | ★ 11.47 | 10.10 |
| 52 Week Low | $8.03 | $4.72 |
| 52 Week High | $15.69 | $15.32 |
| Indicator | CERT | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 57.47 |
| Support Level | $9.06 | $12.31 |
| Resistance Level | $9.45 | $13.29 |
| Average True Range (ATR) | 0.31 | 0.64 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 67.49 | 60.00 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.